Our portfolio is expanding

Our portfolio is expanding 10th June 2024

As from 1st June we are distributing products to hospitals on behalf of Hikma Pharmaceuticals, adding to our growing portfolio of products and manufacturers.

If you are a manufacturer or hospital and want to know more about how Mawdsleys can support and work with you, contact us today at info@mawdsleys.co.uk

Other latest news

Mawdsleys and Meabco launch a Named Patient Supply program for BP-C1

Mawdsleys and Meabco A/S have launched a Named Patient Supply program to allow Oncologists within the European Union (EU) to obtain access to BP-C1 on an unlicensed basis for the treatment of metastatic breast cancer and incurable pancreatic cancer. BP-C1 is a new benzene-poly-carboxylic acids complex with cis-diammineplatinum (II)…

Morningside Pharmaceuticals add Mawdsleys as a distributor to Hospitals

Mawdsleys is delighted to now be partnering with Morningside Pharmaceuticals as an additional distributor to supply their contract and non-contract products to hospitals. Morningside has a portfolio of 242 generic and branded licensed medicines in the UK and EU and is a proud manufacturer and supplier to NHS Trusts,…